pubrio

FREE TRIAL - NO CARD NEEDED

Close deals with the right data at the right time.

Pubrio gives your team the data, timing, and tools to reach the right prospects before the competition does.

Company & people search

Filter 560M+ contacts by role, industry, tech stack & more.

Sequences

Automate multi-step outreach without losing the personal touch.

Market signals

Stay ahead of every market shift. Pubrio Signals watches companies for you and delivers the right intelligence.

Start your free trial

Join 9,000+ revenue teams already using Pubrio.

No credit card · Cancel anytime · GDPR safe

Already have an account?Log in

Qiming Venture Partners

Qiming Venture Partners

Hong Kong · Venture Capital And Private Equity Principals

Financial Services

Information Technology & Services

Biotechnology

Venture Capital And Private Equity Principals

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status. Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE:ZH, SEHK:2390), Roborock (SHSE:688169), UBTech (SEHK:9880), WeRide (NASDAQ:WRD), HyperStrong (SHSE:688411), Insta360 (SHSE:688775), Unisound (SEHK:9678), Gan & Lee Pharmaceuticals (SHSE:603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE:688520), Yuanxin Technology, Insilico Medicine, Medilink Therapeutics, LaNova Medicines, zai, StepFun, among many others.

Company Insights
Company Overview

2006

Founded

Venture Capital And Private Equity Principals

Industry

Hong Kong

Location

3,456,995

Ranking

200 employees

Size

Similar Companies
Similiar Companies

Get full access to view complete information

Frequently Asked Questions Regarding Qiming Venture Partners

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

Start Journey Image
pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​

© 2026 Pubrio. All rights reserved.